Filing Flows › Comparisons › OBIO vs RDGL
Orchestra BioMed Holdings vs Vivos: OBIO and RDGL compared
Orchestra BioMed Holdings is the larger company: $88K of revenue in its latest quarter (Q2 2026) against $36K for Vivos (Q2 2026). Vivos is growing faster (+143% against -90% a year earlier).
Where the money goes: OBIO and RDGL
Orchestra BioMed Holdings (OBIO) · Q2 2026
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
Vivos (RDGL) · Q2 2026
Vivos, Q2 2026: revenue $36K (+143% year over year), net loss $830K, operating cash flow −$740K. The chart follows the revenue to costs, profit and cash.
| Orchestra BioMed Holdings (OBIO) | Vivos (RDGL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $88K | $36K |
| Revenue growth, Y/Y | -90% | +143% |
| Operating margin | n/m | n/m |
| Net earnings | −$23.8M | −$830K |
| Operating cash flow | −$19.3M | −$740K |
Questions
Which is bigger, Orchestra BioMed Holdings or Vivos?
Orchestra BioMed Holdings is the larger company: $88K of revenue in its latest quarter (Q2 2026) against $36K for Vivos (Q2 2026).
Is Orchestra BioMed Holdings or Vivos growing faster?
Vivos is growing faster (+143% against -90% a year earlier).
More: Orchestra BioMed Holdings earnings · how Orchestra BioMed Holdings makes money · Vivos earnings · how Vivos makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.